Active substance: artemether
Form: rectal capsules – suppogels
Dosage: 40 mg/ suppogel
Packaging: Box with 1 blister of 6 suppogels
Target : children (6months – 3 y)
Artesiane suppogel is indicated for
Treatment of acute malaria attacks due to Plasmodium falciparum. Rectal
capsules /suppogels are intended for emergency treatment, at a time when the
administration of other forms is difficult or impossible. This medication is available to mothers to treat their adolescents in the absence of medical help.
This presentation applies in particular to rural areas of developing countries.
According to the recommendations, a monotherapy treatment with Artesiane Suppogel should be followed by a complete cure with an effective oral CTA.
Artesiane Suppogel is specifically indicated in the pre-transfer treatment of severe malaria. In the case of a suspected severe malaria, and when the time between the transfer of the patient to the care unit and the start of treatment is more than 6 hours, pre-transfer treatment is recommended. If a transfer is impossible the treatment should take its course until the patient is able to take oral treatment and complete a cure with an effective CTA.
The dose depends on the severity of the case and the clinical state of the patient.
Starting dose: 4 mg/kg bodyweight on the first day
Following days: Dose of 2mg/kg bodyweight from day 2 off.
Rectal capsules (suppogels) are generally administered to children and adolescent and to elderly having difficulties of swallowing oral forms, or having gastro-intestinal problems, as well as in severe cases such as neuromalaria, with decreased consciousness or in the event of a coma. When the patient regains consciousness or, in the absence of gastrointestinal problems, treatment will be followed by oral treatment with an effective CTA.
Rectal administration. The capsule is inserted in the anus and pushed into the rectum. In case needed, the patient is kept lying down avoiding that the capsule is pushed out.
Prescription drugs. Please contact your doctor.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Dear valued partners, customers and Dafra representatives,
It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.
Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.
We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.
We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.
As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.
Thank you for your continued support and trust in our company.
Dafra Pharma